深圳商报·读创客户端记者穆砚 2月27日晚间，上海复旦张江生物医药股份有限公司（以下简称“复旦张江”或“公司”）发布2025年度业绩快报公告。公告显示，公司业绩遭遇断崖式反转，全年实现营业总收入6.857亿元，同比下降3.33%，归母净利润由上年盈利3973.39万元转为亏损1.57亿元，同比降幅高达496.23%，盈利能力彻底崩塌。核心诱因是核心产品里葆多®未中选国家集采，公司调整销售策略导致...
Source Link深圳商报·读创客户端记者穆砚 2月27日晚间，上海复旦张江生物医药股份有限公司（以下简称“复旦张江”或“公司”）发布2025年度业绩快报公告。公告显示，公司业绩遭遇断崖式反转，全年实现营业总收入6.857亿元，同比下降3.33%，归母净利润由上年盈利3973.39万元转为亏损1.57亿元，同比降幅高达496.23%，盈利能力彻底崩塌。核心诱因是核心产品里葆多®未中选国家集采，公司调整销售策略导致...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.